nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.04.2010 | Image of the month

PET/CT imaging of osteoblastic bone metastases with ⁶⁸Ga-bisphosphonates: first human study

verfasst von: Marco Fellner, Richard P. Baum, Vojtěch Kubíček, Petr Hermann, Ivan Lukeš, Vikas Prasad, Frank Rösch

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Excerpt

Bisphosphonates are well established ligands for ^99mTc for planar and SPECT/CT imaging of osteoblastic metastases. A novel DOTA-based bisphosphonate, (4-{[bis-(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl)acetic acid (BPAMD) [1, 2], was labelled using the ⁶⁸Ge/⁶⁸Ga generator-derived positron emitter ⁶⁸Ga [3], resulting in the PET tracer [⁶⁸Ga]BPAMD. …

Kubícek V, Rudovský J, Kotek J, Hermann P, Vander Elst L, Muller RN, et al. A bisphosphonate monoamide analogue of DOTA: a potential agent for bone targeting. J Am Chem Soc 2005;127(47):16477–85.CrossRefPubMed

Vitha T, Kubícek V, Hermann P, Elst LV, Muller RN, Kolar ZI, et al. Lanthanide(III) complexes of bis(phosphonate) monoamide analogues of DOTA: bone-seeking agents for imaging and therapy. J Med Chem 2008;51(3):677–83.CrossRefPubMed

Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007;48(10):1741–8.CrossRefPubMed

Titel: PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosphonates: first human study
verfasst von: Marco Fellner
Richard P. Baum
Vojtěch Kubíček
Petr Hermann
Ivan Lukeš
Vikas Prasad
Frank Rösch
Publikationsdatum: 01.04.2010
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 4/2010
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-009-1355-y

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate

Highlights of the EANM Congress Barcelona 2009: increasing our impact in diagnostic imaging

Erratum to: Clinical impact of 11C-methionine PET on expected management of patients with brain neoplasm

Five months’ follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by 131I-SPECT/CT at the first radioablation

Revisiting the prognostic value of preoperative 18F-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC)

18F-FDG PET in stage IB/IIB cervical adenocarcinoma/adenosquamous carcinoma